脂肪性肝病各亚型肝硬化与肝细胞癌的长期风险
这项前瞻性研究纳入1997至2013年参加健康筛查的332,175名成人,按超声、饮酒模式及心血管代谢危险因素分为代谢功能障碍相关脂肪性肝病(MASLD)、MASLD伴过量饮酒(MetALD)和酒精相关肝病(ALD)等亚型,随访至2019年。中位随访16年,肝硬化与肝细胞癌发病率分别为86.1/10万人年和26.8/10万人年,ALD组最高,其次为MetALD、MASLD和非SLD组;与无心血管代谢危险因素的非SLD相比,MASLD、MetALD和ALD的肝细胞癌多因素校正风险比分别为1.92、2.91和2.59。
要点
- 中位随访16年,队列肝硬化发病率为86.1/10万人年,肝细胞癌为26.8/10万人年。
- 肝硬化与肝细胞癌发病率由高到低依次为ALD组、MetALD组、MASLD组和非SLD组。
- 以无心血管代谢危险因素的非SLD为参照,ALD的肝硬化风险比为4.74。
核心结论
- 与无心血管代谢危险因素的非SLD相比,MASLD、MetALD和ALD的肝细胞癌多因素校正风险比分别为1.92(95%CI 1.51-2.44)、2.91(95%CI 2.11-4.03)和2.59(95%CI 1.93-3.48),肝硬化风险模式相似(均P<0.001)。
- 研究强调SLD各亚型肝硬化与肝细胞癌风险升高,并强调行为干预对早期预防的重要性。
研究设计与样本
- 前瞻性研究,纳入1997至2013年参加健康筛查项目的332,175名成人,按超声、饮酒模式及心血管代谢危险因素分为MASLD、MetALD、ALD和非SLD等亚型。
- 通过计算机化数据链接全国登记系统(1997至2019年)确认肝硬化与肝细胞癌发病。
主要发现
- 中位随访16年,整个队列发生肝硬化4,458例、肝细胞癌1,392例,发病率分别为86.1/10万人年和26.8/10万人年。
- ALD组肝硬化与肝细胞癌发病率最高,其次为MetALD组、MASLD组和非SLD组。
- 与无心血管代谢危险因素的非SLD相比,MASLD、MetALD和ALD的肝细胞癌多因素校正风险比分别为1.92(95%CI 1.51-2.44)、2.91(95%CI 2.11-4.03)和2.59(95%CI 1.93-3.48)。
- 以无心血管代谢危险因素的非SLD为参照,ALD的肝硬化风险比为4.74(95%CI 4.08-5.52),肝硬化风险模式与肝细胞癌相似(均P<0.001)。
临床怎么用
- 研究强调行为干预对SLD各亚型肝硬化与肝细胞癌早期预防的重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prospective study aimed to investigate the long-term associated risks of cirrhosis and hepatocellular carcinoma (HCC) across various subtypes of steatotic liver disease (SLD). METHODS: We enrolled 332,175 adults who participated in a health screening program between 1997 and 2013. Participants were categorized into various subtypes, including metabolic dysfunction-associated SLD (MASLD), MASLD with excessive alcohol consumption (MetALD), and alcohol-related liver disease (ALD), based on ultrasonography findings, alcohol consumption patterns, and cardiometabolic risk factors. We used computerized data linkage with nationwide registries from 1997 to 2019 to ascertain the incidence of cirrhosis and HCC. RESULTS: After a median follow-up of 16 years, 4,458 cases of cirrhosis and 1,392 cases of HCC occurred in the entire cohort, resulting in an incidence rate of 86.1 and 26.8 per 100,000 person-years, respectively. The ALD group exhibited the highest incidence rate for cirrhosis and HCC, followed by MetALD, MASLD, and non-SLD groups. The multivariate adjusted hazard ratios for HCC were 1.92 (95% confidence interval [CI] 1.51-2.44), 2.91 (95% CI 2.11-4.03), and 2.59 (95% CI 1.93-3.48) for MASLD, MetALD, and ALD, respectively, when compared with non-SLD without cardiometabolic risk factors. The pattern of the associated risk of cirrhosis was similar to that of HCC (all P value <0.001). The associated risk of cirrhosis for ALD increased to 4.74 (95% CI 4.08-5.52) when using non-SLD without cardiometabolic risk factors as a reference. DISCUSSION: This study highlights elevated risks of cirrhosis and HCC across various subtypes of SLD compared with non-SLD, emphasizing the importance of behavioral modifications for early prevention.
引用
- Chen YT, Chen TI, Yang TH, et al. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes. Am J Gastroenterol. 2024. PMID: 38534155. doi:10.14309/ajg.0000000000002778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。